Inutility of IMP3 Marker in Differentiating Hodgkin Lymphoma from Large Cell Lymphoma

A. Z. Mehrjerdi, M. Ahmadi
{"title":"Inutility of IMP3 Marker in Differentiating Hodgkin Lymphoma from Large Cell Lymphoma","authors":"A. Z. Mehrjerdi, M. Ahmadi","doi":"10.18502/BCCR.V12I1.5730","DOIUrl":null,"url":null,"abstract":"Background: Hodgkin’s lymphoma is one of the most commonly diagnosed lym- phomas in Western society. Today Reed-Sternberg cells are identified by positive staining of several biomarkers. The IMP3 (insulin-like growth factor II m-RNA-bind- ing protein 3) marker is a member of the insulin-like growth factor II mRNA binding protein family that has been suggested as a diagnostic marker in some epithelial malignancies. In this study, we aimed to evaluate the expression profile of IMP3 in Hodgkin’s lymphoma patients and compare it with those with large cell lymphoma. \nMethods: In this study, patients diagnosed with Hodgkin’s lymphoma between 2016 and 2018 were recruited. For the control group, patients diagnosed with large cell lymphoma were chosen. Paraffin blocks were collected and cut by a microtome machine. Immunohistochemical staining was performed on the slides for the IMP3 marker, using the Envision method. The color intensity was divided into four groups, and data on age, gender, staining intensity, sampling rate, and staining pattern en- tered at the end of the checklists. The collected data were analyzed using SPSS 19 software. The paired t-test has was employed, and a significant statistical level of 0.05 was considered in all tests. \nResults: In this study, 145 patients in a wide range of 5 to 84 years (the mean age = 41 ± 17 years) were studied. Fifty-three patients were diagnosed with diffuse large B-cell lymphoma (36.6%), 4 cases (2.8%) with anaplastic large cell lymphoma and 88 cases with (60.7%) Hodgkin’s lymphoma. Among 145 patients in the current study, 143 patients (98.6%) were positive for IMP3. IMP3 was positive in all patients with Hodgkin’s lymphoma and anaplastic large cell lymphoma, and only 2 cases of diffuse large B-cell lymphoma were negative for this maker, in whom severe ne- crosis was noted. Consequently, there is not a vivid difference between Hodgkin’s lymphoma and non-Hodgkin’s lymphoma (p-value=0.153) \nConclusion: The marker is positive for Hodgkin’s lymphoma with a negative back- ground and may be used as a supplementary marker along with CD15 and CD30 to detect neoplastic cells. However, it cannot help differentiate it from large cell lym- phomas because it is also positive for non-Hodgkin lymphomas.","PeriodicalId":8706,"journal":{"name":"Basic & Clinical Cancer Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic & Clinical Cancer Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/BCCR.V12I1.5730","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Hodgkin’s lymphoma is one of the most commonly diagnosed lym- phomas in Western society. Today Reed-Sternberg cells are identified by positive staining of several biomarkers. The IMP3 (insulin-like growth factor II m-RNA-bind- ing protein 3) marker is a member of the insulin-like growth factor II mRNA binding protein family that has been suggested as a diagnostic marker in some epithelial malignancies. In this study, we aimed to evaluate the expression profile of IMP3 in Hodgkin’s lymphoma patients and compare it with those with large cell lymphoma. Methods: In this study, patients diagnosed with Hodgkin’s lymphoma between 2016 and 2018 were recruited. For the control group, patients diagnosed with large cell lymphoma were chosen. Paraffin blocks were collected and cut by a microtome machine. Immunohistochemical staining was performed on the slides for the IMP3 marker, using the Envision method. The color intensity was divided into four groups, and data on age, gender, staining intensity, sampling rate, and staining pattern en- tered at the end of the checklists. The collected data were analyzed using SPSS 19 software. The paired t-test has was employed, and a significant statistical level of 0.05 was considered in all tests. Results: In this study, 145 patients in a wide range of 5 to 84 years (the mean age = 41 ± 17 years) were studied. Fifty-three patients were diagnosed with diffuse large B-cell lymphoma (36.6%), 4 cases (2.8%) with anaplastic large cell lymphoma and 88 cases with (60.7%) Hodgkin’s lymphoma. Among 145 patients in the current study, 143 patients (98.6%) were positive for IMP3. IMP3 was positive in all patients with Hodgkin’s lymphoma and anaplastic large cell lymphoma, and only 2 cases of diffuse large B-cell lymphoma were negative for this maker, in whom severe ne- crosis was noted. Consequently, there is not a vivid difference between Hodgkin’s lymphoma and non-Hodgkin’s lymphoma (p-value=0.153) Conclusion: The marker is positive for Hodgkin’s lymphoma with a negative back- ground and may be used as a supplementary marker along with CD15 and CD30 to detect neoplastic cells. However, it cannot help differentiate it from large cell lym- phomas because it is also positive for non-Hodgkin lymphomas.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
IMP3标记物在霍奇金淋巴瘤与大细胞淋巴瘤鉴别中的作用
背景:霍奇金淋巴瘤是西方社会最常见的淋巴瘤之一。今天,Reed-Sternberg细胞是通过几种生物标志物的阳性染色来鉴定的。IMP3(胰岛素样生长因子II m- rna结合蛋白3)标记物是胰岛素样生长因子II mRNA结合蛋白家族的成员,已被认为是一些上皮恶性肿瘤的诊断标记物。在本研究中,我们旨在评估IMP3在霍奇金淋巴瘤患者中的表达谱,并将其与大细胞淋巴瘤患者进行比较。方法:本研究招募2016年至2018年诊断为霍奇金淋巴瘤的患者。对照组选择确诊为大细胞淋巴瘤的患者。石蜡块收集,切片机切割。使用Envision方法对载玻片进行IMP3标记物的免疫组织化学染色。颜色强度分为四组,年龄,性别,染色强度,采样率和染色模式的数据记录在检查表的最后。采用SPSS 19软件对收集的数据进行分析。采用配对t检验,所有检验均考虑0.05的显著性统计水平。结果:本研究纳入145例患者,年龄5 ~ 84岁,平均年龄41±17岁。弥漫性大b细胞淋巴瘤53例(36.6%),间变性大细胞淋巴瘤4例(2.8%),霍奇金淋巴瘤88例(60.7%)。在本研究的145例患者中,143例(98.6%)患者IMP3阳性。所有霍奇金淋巴瘤和间变性大细胞淋巴瘤患者均检测到IMP3阳性,仅2例弥漫性大b细胞淋巴瘤患者检测到该抗原阴性,并伴有严重的坏死。结论:该标志物在背景阴性的霍奇金淋巴瘤中呈阳性,可与CD15、CD30一起作为肿瘤细胞检测的辅助标志物。然而,它不能帮助区分大细胞淋巴瘤,因为它对非霍奇金淋巴瘤也呈阳性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
16
审稿时长
12 weeks
期刊最新文献
The Effect of Ursodeoxycholic acid and N-acetyl cysteine on Lymphoblast Viability Cross-Reacting Material 197, a Specific Inhibitor of HB-EGF, and Its Anticancer Effects Chronic Myeloid Leukemia in a Young Man with Unusual Presentation of Weight Loss, Bone Pain, and Abdominal Pain Effects of Gold Nanoparticles on Proton Therapy for Breast Cancer Cancer has an Independent Association with Death in Hospitalized Patients with COVID-19: A Single-center Study in Iran
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1